DEFA14A: CytoDyn Secures $30M Equity Commitment from Yorkville

CytoDyn Inc. announced a $30 million standby equity purchase agreement with Yorkville Advisors Global to provide flexible capital for working capital and general corporate purposes.

Summary

• CytoDyn Inc. entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (Yorkville) on November 3, 2025.
• The agreement provides CytoDyn with the right, but not the obligation, to sell up to $30,000,000 of its common stock to Yorkville over a 36-month period.
• Yorkville is obligated to purchase shares at 98% of the lowest daily Volume Weighted Average Price (VWAP) during a three-consecutive-trading-day pricing period, with CytoDyn having the option to set a minimum acceptable price.
• Proceeds from the sales are expected to be used for working capital, general corporate purposes, and debt repayment.
• CytoDyn paid Yorkville a $25,000 structuring fee and will pay a commitment fee of 1.00% of the $30,000,000 commitment ($300,000) in common shares, issued in two tranches.
• The agreement includes limitations, such as Yorkville not beneficially owning more than 4.99% of CytoDyn's outstanding voting power or shares, and individual advances not exceeding 100% of the average daily traded amount over the five preceding trading days.
• The Company must file a registration statement with the SEC to register the resale of the commitment shares and shares issued under advances.

Sentiment

Score: 6

Explanation: The agreement provides a much-needed flexible funding source for a clinical-stage company, which is positive for operational continuity and drug development. However, the inherent dilution from selling shares at a discount and the commitment fee, coupled with the ongoing need for capital, temper the overall sentiment. It's a necessary step but not a transformative one in terms of value creation without significant clinical progress.

Positives

• Secured a flexible funding commitment of up to $30 million without mandatory minimum draws or usage penalties.
• No warrants, derivatives, or other share classes are associated with the funding arrangement, simplifying the capital structure.
• The Company retains sole discretion over the timing of stock sales, providing control over potential dilution.
• The funding is intended for working capital, general corporate purposes, and debt repayment, which can strengthen the balance sheet.
• The agreement does not impose restrictions on the Company's operating activities.
• The Company represents it has not entered into any Variable Rate Transaction, avoiding certain highly dilutive financing structures.

Negatives

• The sale of common stock at 98% of VWAP implies a discount to the market price, leading to dilution for existing shareholders.
• The commitment fee of 1.00% ($300,000) is paid in common shares, causing immediate dilution.
• The Company acknowledges that the issuance of common shares could cause dilution to existing shareholders and significantly increase the outstanding number of common shares.
• Yorkville's obligation to purchase shares is subject to conditions, including an effective registration statement, which introduces a dependency.
• The 4.99% ownership limitation for Yorkville could restrict the size or frequency of advances if Yorkville approaches this threshold.

Risks

• Actual results, levels of activity, performance, or achievements may be materially different from forward-looking statements due to business, economic, and other known and unknown risks and uncertainties.
• Risks related to the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy.
• The issuance of common shares under the agreement could cause dilution to existing shareholders and significantly increase the outstanding number of common shares.
• The Company's ability to draw on the commitment is contingent on maintaining an effective registration statement with the SEC.
• Trading in the Common Shares could be suspended or delisted from the Principal Market, or DTC services restricted, which would impact the ability to make advances.
• The Company's failure to perform its obligations under the agreement could lead to losses for the Investor.

Future Outlook

CytoDyn expects to utilize the proceeds from this funding commitment for working capital and general corporate purposes, including the repayment of debt. The Company intends to further develop its program centered around leronlimab's ability to upregulate PD-L1, while maintaining flexibility to pursue additional financings or strategic partnerships.

Management Comments

• "This funding commitment from Yorkville is a solid step in the right direction for CytoDyn." Robert E. Hoffman, CFO.
• "We will utilize this underlying commitment to further develop our program centered around the ability of leronlimab to upregulate PD-L1." Robert E. Hoffman, CFO.
• "This type of discretionary arrangement allows us continued flexibility as we look to bring in additional capital, whether it be through additional financings or strategic partnerships." Robert E. Hoffman, CFO.

Industry Context

This financing provides CytoDyn, a clinical-stage oncology company, with a flexible capital source to continue its drug development efforts for leronlimab. In the biotechnology and pharmaceutical industry, securing non-dilutive or flexible equity financing is crucial for companies without consistent revenue streams, especially those in clinical stages. The focus on leronlimab's ability to upregulate PD-L1 aligns with current trends in immuno-oncology, where PD-L1 modulation is a significant area of research for cancer therapies.

Comparison to Industry Standards

• The standby equity purchase agreement (SEPA) structure is a common financing tool for smaller, clinical-stage biotechnology companies, similar to those used by companies like Sorrento Therapeutics (SRNE) or Aeterna Zentaris (AEZS) in their early development phases.
• The 98% of VWAP pricing mechanism is typical for such agreements, offering a slight discount to market for the investor in exchange for commitment and flexibility for the company.
• The 1.00% commitment fee is within the standard range for similar standby equity facilities provided by institutional investors like Yorkville Advisors.
• The 4.99% beneficial ownership limitation for the investor is a standard provision to avoid triggering certain reporting requirements or control thresholds.
• The use of proceeds for working capital and debt repayment is a common and necessary application of funds for clinical-stage companies, comparable to how many emerging biotech firms manage their liquidity.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the issuance of new common shares at a discount to market price and the commitment fee paid in shares. However, the funding provides capital for ongoing operations and drug development, which could preserve or enhance long-term value if successful.
• Employees: Continued employment and stability as the company secures funding for operations.
• Creditors: Potential for debt repayment, which could improve the company's credit profile.
• Customers/Patients: Continued progress in clinical trials for leronlimab, potentially leading to new therapeutic options.

Next Steps

• CytoDyn will file a registration statement with the SEC to register the resale of the commitment shares and shares issued under advances.
• The Company will continue to develop its leronlimab program, focusing on its ability to upregulate PD-L1.
• Management will explore additional financings or strategic partnerships.
• Yorkville will receive the first half of the commitment fee shares within five days of November 3, 2025, and the remaining half on the six-month anniversary.

Key Dates

Recommendation

The standby equity purchase agreement provides CytoDyn with a crucial and flexible funding mechanism, which is essential for a clinical-stage biotechnology company to continue its research and development, particularly for leronlimab. This reduces immediate liquidity concerns and allows for strategic deployment of capital for working capital and debt repayment. However, the inherent dilutive nature of equity financing at a discount to market, coupled with the commitment fee, means existing shareholders will bear the cost of this capital. While the funding is a positive for operational stability, it does not fundamentally alter the company's long-term value proposition without significant positive clinical trial results or strategic partnerships. Therefore, a 'hold' recommendation is appropriate, acknowledging the improved financial flexibility while recognizing the ongoing risks and dilution.

Keywords

CytoDyn, CYDY, Yorkville Advisors, Standby Equity Purchase Agreement, SEPA, Equity Financing, Capital Raise, Dilution, Working Capital, Debt Repayment, Leronlimab, Oncology, Clinical-stage, CCR5 receptor, TNBC, mCRC